MRUS - メルス (Merus N.V.) メルス

 MRUSのチャート


 MRUSの企業情報

symbol MRUS
会社名 Merus NV (メルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include among others MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.   メルスはオランダのバイオ医薬品企業。臨床段階で、主に二重特異性抗体医薬の開発に焦点を当てる。同社パイプラインは、がん腫瘍細胞の生存と成長を引き起こすレセプタ―をブロックして、腫瘍を根絶するためにキラ―細胞を起動させることによって、患者の免疫機能に働きかける。前臨床試験において効果を示す。本社はユトレヒト。   Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
本社所在地 Yalelaan 62 Utrecht 3584 CM NLD
代表者氏名 Mark T. Iwicki Mark T. Iwicki
代表者役職名 Chairman of the Supervisory Board
電話番号 +31 30-253-8800
設立年月日 37773
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 83人
url www.merus.nl
nasdaq_url https://www.nasdaq.com/symbol/mrus
adr_tso
EBITDA EBITDA(百万ドル) -44.48295
終値(lastsale) 18.18
時価総額(marketcap) 411464304
時価総額 時価総額(百万ドル) 366.52000
売上高 売上高(百万ドル) 27.34463
企業価値(EV) 企業価値(EV)(百万ドル) 127.73490
当期純利益 当期純利益(百万ドル) -49.48767
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Merus NV revenues increased 63% to EUR16.5M. Net loss decreased 67% to EUR13M. Revenues reflect Collaboration income increase from EUR2.4M to EUR7.2M Up-front payment amortization increase of 32% to EUR9.1M. Lower net loss reflects Net loss on foreign exchange decrease from EUR12M (expense) to EUR0K Interest expense decrease of 100% to EUR1K (expense).

 MRUSのテクニカル分析


 MRUSのニュース

   Merus N.V.: Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update  2023/02/28 21:34:00 Finanz Nachrichten
- Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 - Petosemtamab clinical and regulatory update planned for first half of 2023 …
   Can you still get a good price for Merus N.V. (MRUS) Shares at this point?  2023/02/10 15:08:00 US Post News
In Thursday’s session, Merus N.V. (NASDAQ:MRUS) marked $18.03 per share, up from $16.02 in the previous session. While Merus N.V. has overperformed by 12.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRUS fell by -28.34%, with highs and lows ranging from $30.81 to $12.03, whereas […]
   Merus N.V. PT Lowered to $35 at Guggenheim  2023/01/03 12:42:15 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-receives-investment-bank-analyst-rating-update-432SI-2972255
   Merus: Market Pricing In Further Downside (NASDAQ:MRUS)  2022/12/25 13:45:41 Seeking Alpha
Merus traded with wide-reaching volatility over the past 2 years. Read more to see my thoughts on its Zenocutuzumab trial and why we''re on the sidelines for now.
   Merus N.V. PT Lowered to $46 at BMO Capital  2022/12/20 09:13:02 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-lowered-to-46-at-bmo-capital-432SI-2967652
   Do investors need to be concerned about Merus N.V. (MRUS)?  2022/11/24 14:48:00 US Post News
Merus N.V. (NASDAQ:MRUS) closed Wednesday at $15.53 per share, down from $15.94 a day earlier. While Merus N.V. has underperformed by -2.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRUS fell by -38.81%, with highs and lows ranging from $33.09 to $12.03, whereas the simple […]
   Can Merus N.V. (NASDAQ: MRUS) Still Be Considered A Loss When It’s Down -48.58% YTD?  2022/11/19 13:30:00 Marketing Sentinel
During the last session, Merus N.V. (NASDAQ:MRUS)’s traded shares were 0.89 million, with the beta value of the company hitting 0.92. At the end of the trading day, the stock’s price was $16.35, reflecting an intraday loss of -4.16% or -$0.71. The 52-week high for the MRUS share is $33.09, that puts it down -102.39 … Can Merus N.V. (NASDAQ: MRUS) Still Be Considered A Loss When It’s Down -48.58% YTD? Read More »
   Merus N.V. PT Lowered to $30 at Citi  2022/11/15 21:15:04 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-lowered-to-30-at-citi-432SI-2945083
   Merus N.V. (MRUS) can beat the pack with these strategies  2022/11/07 14:32:00 US Post News
Merus N.V. (NASDAQ:MRUS) marked $17.07 per share on Friday, up from a previous closing price of $15.28. While Merus N.V. has overperformed by 11.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRUS fell by -45.62%, with highs and lows ranging from $33.09 to $12.03, whereas […]
   Merus N.V. (NASDAQ:MRUS) Is 16.18% Above Its 52-Week Low, But How Long Can It Continue?  2022/11/03 18:00:00 Marketing Sentinel
In recent trading session, Merus N.V. (NASDAQ:MRUS) saw 1.11 million shares changing hands at last check today with its beta currently measuring 0.93. Company’s recent per share price level of $16.07 trading at -$4.31 or -21.15% at last check today assigns it a market valuation of $926.27M. That most recent trading price of MRUS’s stock … Merus N.V. (NASDAQ:MRUS) Is 16.18% Above Its 52-Week Low, But How Long Can It Continue? Read More »
   Merus N.V. PT Raised to $39 at SVB Leerink  2022/10/12 17:41:01 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-raised-to-39-at-svb-leerink-432SI-2910858
   Merus NV (MRUS) Investor Presentation- Slideshow (NASDAQ:MRUS)  2022/09/19 14:23:26 Seeking Alpha
The following slide deck was published by Merus N.V.
   Merus (MRUS) Investor Presentation - Slideshow (NASDAQ:MRUS)  2022/09/09 21:18:28 Seeking Alpha
The following slide deck was published by Merus N.V.
   Merus N.V.: Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics  2022/09/07 20:17:00 Finanz Nachrichten
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022(Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispeci…
   MRUS stock gains as Stifel initiates with Buy on three bispecific antibodies (NASDAQ:MRUS)  2022/08/02 17:28:39 Seeking Alpha
The shares of Dutch biotech Merus N.V. (MRUS) added ~8% on Tuesday after Stifel initiated its coverage on the stock with a Buy recommendation as the analysts weighed in on the potential…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メルス MRUS Merus N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)